-
Mashup Score: 0Developing targeted therapies to address heterogeneity in AML - 8 month(s) ago
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the heterogeneity of acute myeloid leukemia (AML) and how this impacts treatment approaches for patients. Dr Fathi explains that AML can involve different mutations and pathways across patients, but the primary treatment strategy remains to be intensive chemotherapy. Dr Fathi therefore notes that targeted therapies are currently being developed which could be combined with traditional treatments to reduce toxicity while maintaining high efficacy. To conclude, Dr Fathi highlights an ongoing Phase II multicenter study (NCT04801797) comparing intensive chemotherapy with the non-intensive azacitidine/venetoclax combination regimen in patients with AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reser
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Information Specialists | Leukemia and Lymphoma Society - 2 year(s) ago
We will be closed Monday September 5th for the Labor Day Holiday Speak one-on-one with an Information Specialist who can assist you through cancer treatment, financial and social challenges and give accurate, up-to-date disease, treatment and support information. Our Information Specialists are highly trained oncology social workers and nurses. How to…
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Today on #WorldLeukemiaDay, we're helping to shed light on leukemia during #BloodCancerAwarenessMonth! 🗓️ We are here for support, resources and education for patients and families 👉 https://t.co/5HaIOaCoSu @AcuteLeuk https://t.co/qN0hoZgxYN
-
-
Mashup Score: 4World Leukemia Day 2021 - 3 year(s) ago
World Leukemia Day is September 4th 2021. Find out about the ways you can get involved, spread awareness and take action.
Source: World Leukemia DayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Saturday was #WLD21 #WorldLeukemiaDay. In recognition and to help raise awareness, we are making our latest content in leukaemia research free to access with registration until Sept 20 🧵 https://t.co/9XjEKOiYV1 @AcuteLeuk @CLLAdvocates @cmlnet @LeukaemiaCareUK https://t.co/uaszfGycs6
-
-
Mashup Score: 0
The addition of ublituximab to ibrutinib resulted in a statistically higher overall response rate without affecting the safety profile of ibrutinib monotherapy in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia. These findings provide support for the addition of ublituximab to Bruton tyrosine kinase inhibitors for the treatment of these patients.
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Results from the phase 3, GENUINE trial show the addition of ublituximab to ibrutinib improves overall response without affecting the safety profile of ibrutinib monotherapy in patients with r/r high-risk #CLL. #leusm #WLD21 #WorldLeukemiaDay https://t.co/NpQ3tocbWQ https://t.co/JHemcBC8oA
-
-
Mashup Score: 1Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study - 3 year(s) ago
These data suggest hypomethylating agents as the preferred therapy for patients with higher-risk chronic myelomonocytic leukaemia and those with myeloproliferative CMML. Our findings also suggest that CPSS is a valuable tool to identify patients who are most likely to benefit from hypomethylating agents. Further evidence from prospective cohorts would be desirable.
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A retrospective study in 949 patients suggests that hypomethylating agents are the preferred first-line therapy for patients with high-risk or myeloproliferative CMML #leusm #WLD21 #WorldLeukemiaDay https://t.co/3KR8xhj8RA https://t.co/TIzOIzqoBQ
-
-
Mashup Score: 1
Children with ABL-class fusion B-cell acute lymphocytic leukaemia have poor outcomes when treated with regimens that do not contain a tyrosine-kinase inhibitor, despite the use of high-risk chemotherapy regimens and frequent HSCT upon first remission. Our findings provide a reference for evaluating the potential benefit of first-line tyrosine-kinase inhibitor treatment in patients with ABL-class…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A retrospective study in 122 paediatric patients assesses outcomes of paediatric patients with B-cell ALL with ABL-class fusion in the pre-TKI era, providing a reference for evaluating the potential benefit of TKIs. #leusm #pedonc #WLD21 #WorldLeukemiaDay https://t.co/2me6s6hAW3 https://t.co/M28x4U8NkF
-
-
Mashup Score: 0Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia - 3 year(s) ago
5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Liv Andrés-Jensen et al prioritise and define unacceptable long-term toxicity for patients with childhood AML and define how these toxicities should be combined into a composite quantity to be integrated with other outcomes. #leusm #WLD21 #WorldLeukemiaDay https://t.co/JxXP3GdTFR https://t.co/SO2ztUf3gT
-
-
Mashup Score: 2World Leukemia Day 2020 - 4 year(s) ago
World Leukemia Day is September 4th 2020. Find out about the ways you can get involved, spread awareness and take action.
Source: World Leukemia DayCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrSalamalani: oday is #WorldLeukemiaDay - Help raise awareness here > https://t.co/ndfMSWSH5g…… #WLD20 @LeukaemiaCareUK @AcuteLeuk @CLL…
-
-
Mashup Score: 0Guideline on the diagnosis and management of chronic myeloid leukaemia | British Society for Haematology - 4 year(s) ago
© British society for Haematology 2018 The British Society for Haematology is registered in England and Wales as a Company Limited by Guarantee, No 2645706 and as a Charity, No 1005735 Registered Office and correspondence address: 100 White Lion Street London N1 9PF. Phone: 020 7713 0990 …
Source: b-s-h.org.ukCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Guideline on the diagnosis and management of chronic myeloid leukaemia. https://t.co/yZzEByFJnO #WorldLeukemiaDay #WLD20
-
-
Mashup Score: 0Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs? - 4 year(s) ago
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Source: Wiley Online LibraryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BJHaem Open Access Paper: Supportive care in the management of patients with acute myeloid leukaemia: where are the research needs? https://t.co/avh4KYUPuq #WorldLeukemiaDay #WLD20
-
Today is #WorldLeukemiaDay. We recently spoke to Amir Fathi of @MassGeneralNews who shared some insights into the heterogeneity of AML & the development of targeted therapies to address this heterogeneity. 🎥 https://t.co/YDrZC7uLtY #LeuSM #AMLsm #WLD23